Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from the June 8, 2026 annual meeting of Franklin BSP Realty Trust, Inc., covering three proposals: election of six directors, ratification of PwC as independent auditor, and an advisory vote on named executive officer compensation. The filing presents detailed voting tallies for each proposal, which is the core content of Item 5.07 disclosures and is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from ClearSign's June 8, 2026 annual meeting. The filing presents detailed voting tallies for five proposals: election of four directors, appointment of auditor BPM CPA LLP, approval of the amended 2021 Equity Incentive Plan, advisory vote on named executive officer compensation, and approval of an adjournment proposal. All proposals passed. This is material as it documents the outcomes of fundamental corporate governance matters including board composition and equity plan authorization.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted at the Company's Annual Meeting on June 9, 2026, approving five proposals: election of five directors, ratification of BDO USA P.C. as auditor, approval of the 2026 Omnibus Incentive Plan, an advisory vote on named executive officer compensation, and an advisory vote on compensation vote frequency.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of an annual meeting of stockholders held on June 3, 2026. The filing presents voting results for two proposals: (1) election of Class II directors (Sashi Brown and Jamila Mayfield, each receiving 21,530,729 votes for and 0 against), and (2) ratification of Ernst & Young LLP as independent auditor (21,530,729 for, 0 against, 1,138,021 abstentions). Director elections and auditor ratifications are material governance matters affecting investor assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from the June 5, 2026 Annual Meeting of Stockholders, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of Deloitte and Touche LLP as auditor, advisory approval of named executive officer compensation, and amendment to the 2018 Omnibus Equity Incentive Plan. All proposals were approved. This is a material event as it reflects stockholder decisions on governance, auditor selection, and equity plan authorization.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Ulta Beauty held its Annual Meeting of Stockholders on June 9, 2026, with shareholders voting on six proposals: election of ten directors, approval of exculpation and forum selection amendments to the certificate of incorporation, ratification of Ernst & Young LLP as auditor, an advisory vote on executive compensation, and approval of the 2026 Incentive Award Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from the June 4, 2026 annual meeting of stockholders. The filing reports the final voting tallies for two proposals: (1) election of Wendell E. Pritchett as a Class III director with 18,436,266 votes for and zero against, and (2) ratification of Deloitte & Touche LLP as independent auditor with identical voting results. This is a routine but material Item 5.07 disclosure required by SEC rules for annual meeting outcomes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Verrica Pharmaceuticals held an Annual Meeting of Stockholders with four proposals: election of directors, advisory approval of named executive officer compensation, ratification of KPMG LLP as auditor, and approval of the Amended and Restated 2018 Equity Incentive Plan. Vote results for all four proposals are disclosed with detailed tallies.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted at the June 3, 2026 Annual Meeting, approving four proposals: election of directors Donna Corley and Tela Mathias as Class II directors, ratification of Deloitte as independent auditor, advisory approval of named executive officer compensation, and approval of a reverse stock split amendment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of the Company's 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting tallies for two proposals: election of three Class I directors (Robert A. Lenz, Rebecca Luse, and Ran Nussbaum) and ratification of BDO USA, P.C. as independent auditor. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Stifel Financial Corp. held its Annual Meeting of Shareholders on June 9, 2026, with shareholders voting on five proposals: election of twelve directors, advisory vote on named executive officer compensation, amendment to the Certificate of Incorporation to increase authorized shares from 197 million to 294 million total shares and from 194 million to 291 million common shares, amendment to the 2001 Incentive Stock Plan to increase share capacity by 9,000,000 shares, and ratification of KPMG LLP as independent auditor. All proposals were approved with detailed voting tallies disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Interactive Strength's June 8, 2026 annual meeting of stockholders. The filing presents voting outcomes for eight proposals, including director elections (Trent A. Ward and Kirsten Bartok Touw), ratification of Deloitte & Touche LLP as auditor, approval of dilutive issuances related to Wattbike and Ergatta acquisitions, stock plan amendments, reverse stock split authority, and advisory votes on executive compensation. The disclosure of shareholder vote results is material as it confirms stockholder approval of significant corporate actions including M&A-related equity issuances and governance matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from the June 5, 2026 Annual Meeting of Stockholders, covering three proposals: election of directors, ratification of the independent auditor (KPMG LLP), and an advisory vote on named executive officer compensation. The filing presents final vote tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from Adaptive Biotechnologies' June 5, 2026 annual meeting, covering three proposals: election of two Class I directors (Hershberg and Owen), advisory vote on 2025 named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed voting tallies and percentages match the shareholder_vote_results taxonomy precisely, and the results are material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Relay Therapeutics held its 2026 Annual Meeting of Stockholders, at which shareholders voted on and approved four proposals: election of class III directors Douglas S. Ingram and Claire Mazumdar, Ph.D.; a non-binding advisory vote on executive compensation; ratification of Ernst & Young LLP as independent auditor; and approval of an amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Talos Energy held its Annual Meeting of stockholders and disclosed voting results on four proposals: election of six director nominees, advisory approval of named executive officer compensation, approval of the Second Amended and Restated 2021 Long Term Incentive Plan (increasing shares by 4.5 million and extending the plan term), and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Axsome's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes for three proposals: election of two Class II directors (Mark Saad and Susan Mahony, Ph.D., MBA), ratification of Deloitte & Touche LLP as independent auditor, and non-binding advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-09
Item 5.07
Enliven Therapeutics held its Annual Meeting of Stockholders on June 9, 2026, with voting results on five proposals: election of two Class III directors (Richard Fair and Lori Kunkel), ratification of Deloitte & Touche LLP as independent auditor, approval to increase authorized common shares from 100 million to 200 million, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted at the June 9, 2026 annual meeting to elect Juergen Eckhardt and Eric Bjerkholt as Class II Directors and to ratify PricewaterhouseCoopers LLP as the Company's independent auditor, with detailed voting tallies disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted at the 2026 Annual Meeting on June 9, 2026, approving three proposals: election of director Todd C. Brady, M.D., Ph.D. (23,026,101 votes for); ratification of BDO USA, P.C. as independent auditor (43,693,772 votes for); and advisory approval of named executive officer compensation (19,477,504 votes for). Vote counts, abstentions, and broker non-votes were disclosed for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This Item 5.07 discloses the results of an annual stockholder meeting covering three proposals: election of three directors (Charles Biederman, Patrick J. Callan Jr., and Jeffrey A. Gould), a non-binding advisory vote on executive compensation for 2025, and ratification of Ernst & Young LLP as independent auditors for 2026. The detailed voting tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure required by Item 5.07, making this a textbook shareholder vote results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
MoonLake Immunotherapeutics held an Annual Meeting of shareholders at which four proposals were voted on and approved: election of Class I director Spike Loy, ratification of Baker Tilly US, LLP as independent auditor, advisory vote on executive compensation, and approval of an amendment and restatement of the 2022 Equity Incentive Plan increasing available shares by 5,000,000 and extending the plan term to 2036.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-09
Item 5.07
This Item 5.07 disclosure reports the final results of Avalon GloboCare's June 9, 2026 annual meeting of stockholders, including voting outcomes on six proposals: director elections, auditor ratification, stock incentive plan approval, say-on-pay advisory vote, warrant issuance approval, and reverse stock split authorization. The detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core content, making this a textbook shareholder_vote_results event. The warrant issuance and reverse split proposals are particularly material to investors assessing dilution and capital structure risk.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Bluejay Diagnostics held its Annual Meeting on June 9, 2026, and reported shareholder voting results on four proposals: director elections, authorization of a reverse stock split, approval of Amendment No. 1 to the 2021 Stock Plan (increasing share reserve by 600,000 shares), and ratification of Wolf & Company as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 75%
filed 2026-06-09
Item 5.07
Nuvve held a special meeting of stockholders on June 9, 2026, which was adjourned due to lack of quorum (2,926,864 shares present fell short of the quorum requirement). The filing discloses the procedural outcome of the meeting adjournment and references Item 8.01 for additional details on the stockholder voting matter.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-09
Item 5.07
Shareholders voted on June 3, 2026 to approve an extension of the Company's business combination deadline from June 6, 2026 to June 6, 2027, with up to twelve one-month extensions, along with related amendments to the Investment Management Trust Agreement.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This 8-K Item 5.07 discloses the final voting results from Exagen Inc.'s 2026 annual meeting of stockholders held on June 9, 2026, covering three proposals: election of two Class I directors (Tina S. Nova and Scott Kahn), ratification of BDO USA, P.C. as independent auditor, and advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are the core disclosure required by Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Palantir's June 3, 2026 annual meeting of stockholders. The filing details voting outcomes for six proposals: election of seven directors (all elected), ratification of Ernst & Young as independent auditor, advisory approval of named executive officer compensation, and three stockholder proposals (all rejected). The detailed vote tallies for each nominee and proposal are the core content of the disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of CervoMed's 2026 Annual Meeting of Stockholders held on June 8, 2026. The filing presents voting results for four proposals: election of eight directors, ratification of RSM US LLP as auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2025 Equity Incentive Plan. All proposals passed with the requisite majorities. This is a material disclosure as it documents shareholder approval of governance and compensation matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
AXT Inc. held its Annual Meeting of Stockholders on June 4, 2026, with shareholders voting on five proposals: election of two Class I directors (Dr. Morris Young and Dr. David Chang), advisory vote on executive compensation, ratification of BPM as independent auditor, approval of an amendment to increase authorized common shares from 70 million to 120 million, and approval of an adjournment proposal. The filing discloses the voting results and outcomes for each matter.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing reports voting outcomes for two proposals: (1) election of directors Jenn Adams and Charles J. Casamento, and (2) ratification of Grant Thornton LLP as independent auditor. The detailed vote tallies (For, Against, Withheld, Abstain, Broker Non-Votes) are presented in tabular form, which is the standard format for Item 5.07 disclosures of shareholder meeting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from the annual meeting held June 9, 2026. The filing reports voting outcomes on four proposals: election of director Robert E. Cauley (4,126,106 for), ratification of BDO USA as auditor (7,408,328 for), approval of Rights Agreement amendment (4,139,041 for), and advisory vote on executive compensation (4,120,960 for). All proposals passed with substantial majorities, making this a material disclosure of shareholder actions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
The filing discloses results of Sanara MedTech's Annual Meeting of Shareholders held on June 4, 2026, under Item 5.07. The company reports voting outcomes for four proposals: election of nine directors, ratification of auditor Weaver and Tidwell L.L.P., advisory approval of named executive officer compensation, and frequency of future advisory votes on compensation. All proposals received sufficient votes for approval, with detailed vote tallies provided for each nominee and proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
The filing discloses Item 5.07 results from XMax Inc.'s June 5, 2026 Annual Meeting of Shareholders, including voting outcomes for four proposals: election of six directors (Umesh Patel, Xiaohua Lu, Yizhou Zhao, Ming-Cherng Sky Tsai, Wen Tao, and Matthew Beck), ratification of Enrome LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. These are standard shareholder vote results that materially affect corporate governance and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-09
The filing discloses results of Fusemachines Inc.'s 2026 Annual Meeting of Stockholders held on June 9, 2026, under Item 5.07. Shareholders voted on three proposals: election of three Class I directors (Salman Alam, Bharat Krish, and Tim Gocher), approval of an amendment to the 2025 Omnibus Equity Incentive Plan to increase available shares by 2,000,000, and ratification of KNAV CPA LLP as independent auditor. Detailed voting results are provided for each proposal, making this a clear shareholder_vote_results disclosure that is material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Fastly held its 2026 Annual Meeting of Stockholders on June 3, 2026, with all three proposals passing by substantial majorities: election of three directors (Álvarez, Compton, Daniels), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This Item 5.07 discloses the results of Oscar Health's 2026 Annual Meeting of Stockholders held on June 4, 2026, including voting outcomes for three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAINED, and Broker Non-Votes) for each proposal and confirms all three items were approved, which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Allegion's 2026 annual general meeting held on June 4, 2026. The filing presents voting outcomes for six proposals: election of eight directors, advisory approval of named executive officer compensation, frequency of future compensation votes, ratification of PricewaterhouseCoopers as auditor, renewal of share issuance authority, and renewal of special share issuance authority. All proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal, which is the hallmark of shareholder vote results reporting.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from Vera Bradley's 2026 Annual Meeting of Shareholders held on June 4, 2026, covering four matters: election of six directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2020 Equity and Incentive Plan. The filing presents detailed vote tallies (for, against, abstentions, and broker non-votes) for each matter, which is the hallmark of Item 5.07 disclosure and constitutes material information for investors regarding corporate governance and shareholder decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Titan Machinery's Annual Meeting held on June 8, 2026. The filing presents voting tallies for three proposals: election of Class I directors (Christianson, Hamilton, Knutson), approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. Shareholder vote results are material to investors as they reflect governance outcomes and stakeholder confidence in management and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Arcutis held its Annual Meeting of Stockholders on June 5, 2026, with shareholders voting on three proposals: election of three Class III directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals were approved.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from Traeger's June 9, 2026 annual meeting of stockholders under Item 5.07. The filing reports voting outcomes for two proposals: (1) election of Class II directors (Martin Eltrich and Steven Richman) with vote tallies, and (2) ratification of Ernst & Young LLP as independent auditor. Both proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and audit oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Alignment Healthcare's annual stockholder meeting held June 4, 2026. The filing presents voting outcomes for three proposals: election of three Class II directors (Jody Bilney, David Hodgson, and Jacqueline Kosecoff), ratification of Deloitte & Touche LLP as independent auditor, and an advisory say-on-pay vote on executive compensation. All three proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm governance and audit oversight decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on June 9, 2026, covering three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. The filing explicitly states the vote tallies and outcomes for each proposal, which is the core content of Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from the June 9, 2026 Annual Meeting of Stockholders. The filing presents detailed vote tallies for four proposals: election of three Class II directors (Amir Bacchus, Mark Thierer, and Lawrence B. Leisure), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and approval of warrant issuance. All proposals passed. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and key corporate governance matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from Klaviyo's 2026 annual meeting held on June 9, 2026, covering three proposals: election of three Class III directors (Jennifer Ceran, Chano Fernández, and Susan St. Ledger), advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. The filing presents detailed voting tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders. The filing presents voting tallies for two proposals: (1) election of eight directors to the Board, with individual vote counts for each nominee (votes for, against, abstained, and broker non-votes), and (2) ratification of Deloitte & Touche LLP as independent auditor. All directors were elected and the auditor was ratified. This is a material disclosure as shareholder voting outcomes affect governance and audit oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
NCR Voyix held its Annual Meeting of Stockholders on June 3, 2026, with shareholders voting on four proposals: election of eight directors, a say-on-pay advisory vote, ratification of PricewaterhouseCoopers LLP as auditor, and approval of the 2026 Stock Incentive Plan. All four proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
Semtech held its Annual Meeting of Stockholders on June 4, 2026, with shareholders voting on four proposals: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2017 Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
Hawthorn Bancshares held its 2026 Annual Meeting of Shareholders on June 2, 2026, with voting results on four proposals: election of four Class I directors, ratification of Forvis Mazars as independent auditor, advisory approval of executive compensation, and frequency of compensation votes.
View raw filing on EDGAR →